Labopharm's Trazodone faces regulatory setback

07/20/2009 | Reuters

Labopharm's once-daily Trazodone failed to gain FDA approval because of manufacturing deficiencies cited by the agency at an Italian facility that produces an ingredient of the antidepressant. Despite the decision, Labopharm said it remains optimistic and will "continue to plan for commercialization of the product."

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care